当前位置: X-MOL 学术Nat. Rev. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
When an embarrassment of riches isn’t enough
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2022-08-08 , DOI: 10.1038/s41571-022-00670-w
Krina Patel 1 , Sagar Lonial 2
Affiliation  

Data on a new treatment approach utilizing bispecific monoclonal antibodies targetting B-cell maturation antigen (BCMA) were recently published, yielding very encouraging results in the setting of relapsed and/or refractory multiple myeloma (RRMM). How to safely and effectively deliver this treatment to patients and where it fits in the RRMM treatment paradigm are important questions for the future.

中文翻译:


当财富的尴尬还不够时



最近发表了利用针对 B 细胞成熟抗原 (BCMA) 的双特异性单克隆抗体的新治疗方法的数据,在复发和/或难治性多发性骨髓瘤 (RRMM) 的治疗中取得了非常令人鼓舞的结果。如何安全有效地向患者提供这种治疗以及它在 RRMM 治疗范式中的适用位置是未来的重要问题。
更新日期:2022-08-08
down
wechat
bug